The week the numbers get audited
Hims & Hers reported second quarter results on Monday, August 10, after market close. LifeMD, Teladoc, Omada, and the rest of the public cohort report in the same window. For one stretch of the year, private operators get audited numbers from companies running the same playbook they are, and this quarter the stakes are unusually high: Q2 2026 is the first quarter reported deep inside the compounding wind-down, mid-pivot, with the revenue mix visibly reorganizing.
We drafted this piece before the first call and are publishing it as the transcripts land. That is deliberate. Every takeaway below is anchored in what was already confirmed going into the prints: the guidance, the disclosed pivots, the channel signals. The frame holds whatever the actuals say, and the table is built so the actuals slot in without rewriting a word.
For the general method of mining earnings season, see Earnings Season Listening Guide: Five Metrics Every Telehealth Operator Should Steal. This post is its Q2-specific companion: five structural questions this week's prints settle.
The setup going into the prints
| Signal | Confirmed going in | What the print settles |
|---|---|---|
| Hims & Hers Q2 revenue | Guidance of $680M to $700M, 25 to 28% growth year over year | Where growth lands inside, or outside, the guided band |
| Hims & Hers profitability | Adjusted EBITDA guidance of $35M to $55M | What the branded transition actually cost in-quarter |
| Branded access at scale | 125,000 branded shipments in the pivot's first six weeks | Whether branded economics hold at full-quarter scale |
| Employer channel | Omada membership up 51% year over year, past 1M members, 150k+ on GLP-1s | Whether benefit-routed growth carried through the half |
| Capital backdrop | Rock Health: $7.4B across 244 deals in H1 2026, 45% of dollars in 20 megadeals | Which public results validate the concentration of capital |
Two notes on using this table. First, everything in the middle column was public before the calls: guidance from the prior report, the shipment figure from the pivot's early disclosure, the membership numbers from investor communications, the funding data from Rock Health's H1 report. Second, the table is built to be refreshed. As transcripts land, the actuals replace the guided ranges, and the takeaways below tell you what each number means. Nothing else in the post has to change.
Takeaway 1: the guidance band is the honest tell
Look at the shape of the guidance before you look at the result. Revenue guided to a tight $20M range, but adjusted EBITDA guided to $35M to $55M: a band whose top is nearly 60% above its bottom. That is management saying, in guidance form, that they could forecast demand but not the cost of the transition quarter: how fast compounded revenue exits, what branded economics replace it with, how much marketing it takes to hold the funnel together while the offer changes underneath it.
The operator translation: if the category's largest brand could not call its own transition margin inside $20M, your branded-era forecast does not deserve a point estimate either. Model your next two quarters as ranges, attach the assumptions that move you inside the range, and grade yourself on assumption accuracy, not point accuracy. Whatever actual EBITDA prints, where it lands inside that band is the single most information-dense number of the season.
Takeaway 2: branded access is now a retention business
The pivot's opening disclosure, 125,000 branded shipments in six weeks, settled the strategic argument months ago: branded access is the floor for serious GLP-1 operators. We covered that turn in The State of DTC Telehealth in 2026: An Operator's Field Report. What it did not settle is what a branded subscriber is worth over twelve months.
That is what this print settles. When patients can buy the same medication from the manufacturer, access stops being the moat and the program becomes the product: clinical wraparound, titration support, refill reliability, the care relationship. Listen for revenue per subscriber, multi-product attach, and any persistence commentary, because those are the branded-era economics you are actually competing on. The playbook argument is in The Branded GLP-1 Era, and the metrics discipline in Subscriber Growth vs. Patient Quality.
Takeaway 3: the employer channel graduated from side bet to signal
Omada went into the prints having told investors membership grew 51% year over year, past one million members, with more than 150,000 of them on GLP-1s. Read that as a channel fact, not a company fact: a seven-figure population is now reaching metabolic care through benefits rather than ads, and employers are actively rebalancing 2027 GLP-1 coverage during the enrollment season that starts next month.
The structural takeaway holds regardless of Omada's exact Q2 line: benefit-routed patients are a compounding acquisition channel with a fraction of consumer CAC, and most DTC brands still have no offering for them. If that is you, the channel map is in The Employer and HSA Channel. The prints tell you how fast to move.
Takeaway 4: capital concentrated, and earnings are its scoreboard
Rock Health counted $7.4B across 244 deals in H1 2026, up from $6.4B a year earlier, with 45% of the dollars packed into 20 megadeals and mental health the top clinical area (Talkiatry at $210M, Grow Therapy at $150M). Fewer, bigger checks means investors are underwriting against reference points, and the reference points are exactly the metrics the public cohort is being graded on this week: durable subscriber economics, margin through the mix shift, channel diversification.
For operators who plan to raise in the next year, this quarter's transcripts are the diligence template. Restate your own metrics in the cohort's vocabulary before an investor does it for you. The funding landscape is mapped in H1 2026 Digital Health Funding: What Founders Are Betting On.
Takeaway 5: the mix shift nobody reports the same way twice
The compounding wind-down sits under every number this season. The comment period on the FDA's proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulks list closed July 30, and the final order is pending with no announced date. So Q2 is the first clean look at how fast compounded revenue is leaving the system and what replaces it: branded access arrangements, service and program fees, orals.
The catch is that every company reports the mix differently, which makes naive comparison worse than useless. Normalize before you benchmark: separate medication economics from care economics, one-time from recurring, cash-pay from benefit-connected. Then do the same exercise on your own P&L. The most valuable output of earnings season is often the restatement of your own mix that the comparison forces.
Turning the prints into one operating review
Do not let three weeks of calls dissolve into headlines. Book one meeting for early September: the five takeaways above as agenda items, each with the actual from the transcripts next to the figure from the setup table, and one decision attached to each. Pull your own numbers alongside them, cohort retention, revenue per patient, channel mix, so the comparison is live rather than rhetorical.
FAQ
What did Hims & Hers guide for Q2 2026? Revenue of $680 million to $700 million, representing 25 to 28% year over year growth, with adjusted EBITDA of $35 million to $55 million. Results were reported August 10, 2026, after market close. The unusually wide EBITDA band reflected uncertainty about the cost of the compounding-to-branded transition.
Why do public telehealth earnings matter for private operators? Because they are the only audited benchmarks in the category. Public companies must disclose what private ones guard: subscriber economics, retention signals, channel mix, and margin structure. Q2 2026 is especially valuable as the first quarter reported deep inside the compounded GLP-1 wind-down.
How is the compounding wind-down changing telehealth revenue mix? Compounded GLP-1 revenue is exiting on a regulatory timeline: the comment period on the FDA's 503B proposal closed July 30, 2026, with the final order pending. Replacing it is branded access, program and service fees, and oral medications, which shifts operator value from supplying medication to running care.
What did Rock Health report for H1 2026 digital health funding? $7.4 billion across 244 deals, up from $6.4 billion in H1 2025, with 45% of capital concentrated in 20 megadeals. Mental health was the top clinical area, led by Talkiatry's $210 million and Grow Therapy's $150 million rounds.